AP@home is an FP7 funded project and Triteq are one of twelve companies involved across Europe. The objective of AP@home is to build and evaluate an artificial pancreas (AP) with automated closed loop glycaemic control for insulin treated patients with diabetes.
AP systems require algorithms using blood glucose levels obtained via glucose monitoring for controlling subcutaneous insulin administration.
The project is in its second year and would like to announce the launch of their new AP@home Internet website. Please take a look at www.apathome.eu.